Sélection groupe < Sélégiline < Sélénium

Facettes :

List of bibliographic references indexed by Sélégiline

Number of relevant bibliographic references: 23.
[0-20] [0 - 20][0 - 23][20-22][20-40]

Ident.	Authors (with country if any)	Title
003584 (2006)	Rivka Inzelberg [Israël] ; Ubaldo Bonuccelli [Italie] ; Edna Schechtman [Israël] ; Ala Miniowich [Israël] ; Rosa Strugatsky [Israël] ; Roberto Ceravolo [Italie] ; Chiara Logi [Italie] ; Carlo Rossi [Italie] ; Colin Klein [Israël] ; J. Martin Rabey [Israël]	Association between amantadine and the onset of dementia in Parkinson's disease
003A84 (2004)	Cheryl H. Waters [États-Unis] ; Kapil D. Sethi [États-Unis] ; Robert A. Hauser [États-Unis] ; Eric Molho [États-Unis] ; John M. Bertoni [États-Unis]	Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3‐month, randomized, placebo‐controlled study
003E24 (2004)	Susan Hollán [Hongrie] ; Lászl Vécsei [Hongrie] ; Kálmán Magyar [Hongrie]	Adverse effects of dopamine potentiation by long‐term treatment with selegiline
004250 (2002)	Manavdeep Grewal [Canada] ; Raed Hawa [Canada] ; Colin Shapiro [Canada]	Treatment of periodic limb movements in sleep with selegiline HCl
004346 (2002)	Christopher G. Goetz [États-Unis] ; Sue Leurgans [États-Unis] ; Rema Raman [États-Unis]	Placebo‐associated improvements in motor function: Comparison of subjective and objective sections of the UPDRS in early Parkinson's disease
004594 (2002)		Treatment of depression in idiopathic Parkinson's disease
004606 (2002)		MAO-B inhibitors for the treatment of Parkinson's disease
004C42 (1999)	A. Churchyard [Royaume-Uni] ; C. J. Mathias [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni]	Selegiline‐induced postural hypotension in Parkinson's disease: A longitudinal study on the effects of drug withdrawal
004D56 (1999)	Robert B. Innis ; Kenneth L. Marek ; Kim Sheff ; Sami Zoghbi ; Joseph Castronuovo [États-Unis] ; Andrew Feigin [États-Unis] ; John P. Seibyl	Effect of treatment with L‐dopa/carbidopa or L‐selegiline on striatal dopamine transporter SPECT imaging with [123I]β‐CIT
004F03 (1998)	Andreas Kupsch [Allemagne] ; Oertel [Allemagne]	Selegiline, pregnancy, and Parkinson's disease
005093 (1998)	Robert A. Hauser [États-Unis] ; Eric Molho [États-Unis] ; Heidi Shale [États-Unis] ; Simon Pedder [États-Unis] ; Ernest E. Dorflinger [États-Unis]	A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients
005171 (1998)	C. W. Olanow [États-Unis] ; C. Mytilineou [États-Unis] ; W. Tatton [États-Unis]	Current status of selegiline as a neuroprotective agent in Parkinson's disease
005428 (1997)	Nathalie Andreu [France] ; Christine Damase-Michel [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; Montastruc [France]	A dose‐ranging study of selegiline in patients with Parkinson's disease: Effect on platelet monoamine oxidase activity
005448 (1997)	P. Lewitt [États-Unis] ; D. Oakes [États-Unis] ; L. Cui [États-Unis]	The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and α-tocopherol
005450 (1997)	J. P. Larsen [Norvège] ; J. Boas [Danemark]	The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability : An interim analysis of a Norwegian-Danish 5-year study
005462 (1997)	J. Lyytinen [Finlande] ; S. Kaakkola [Finlande] ; S. Ahtila [Finlande] ; P. Tuomainen [Finlande] ; H. Ter V Inen [Finlande]	Simultaneous MAO-B and COMT inhibition in L-dopa-treated patients with Parkinson's disease
005978 (1995)	J. C. Garcia-Monco [Espagne] ; A. Padierna ; M. G. Beldarrain	Selegiline, fluoxetine, and depression in Parkinson's disease
005A18 (1995)	T. L. Davis [États-Unis] ; M. Roznoski ; R. S. Burns	Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenalalanine/carbidopa and selegiline
005E40 (1993)	M. B. H. Youdim [Israël] ; P. Riederer	The relevance of glial monoamine oxidase-B and polyamines to the action of selegiline in Parkinson's disease
005E47 (1993)	H. Allain [France] ; Pierre Pollak [France] ; H. C. Neukirch [France]	Symptomatic effect of selegiline in De Novo Parkinsonian patients
005E52 (1993)	V. V. Myllyl [Finlande] ; K. A. Sotaniemi ; J. A. Vuorinen ; E. H. Heinonen	Selegiline in De Novo Parkinsonian patients: the finnish study

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/PascalFr.i -k "Sélégiline" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/PascalFr.i  \
                -Sk "Sélégiline" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    PascalFr.i
   |clé=    Sélégiline
}}

---

This area was generated with Dilib version V0.6.23. Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024